Beyond hyperkalemia

β-blocker-induced cardiac arrest for normothermic cardiac operations

Mauricio Ede, Jian Ye, Lori Gregorash, Randy Summers, Shirish Pargaonkar, Daniel LeHouerou, Arrigo Lessana, Tomas Salerno, Roxanne Deslauriers

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Four experimental protocols were carried out to assess the ability of esmolol to induce and maintain reversible cardiac arrest under continuous normothermic (37°C) perfusion. Methods and results. In the first protocol, 8 perfused rat hearts were subjected to 20, 60, 90, and 120 minutes of esmolol arrest, after which positive and negative first derivative of pressure, heart rate, left ventricular developed pressure, and left ventricular end-diastolic pressure were evaluated. Arrest was achieved 45 to 60 seconds after beginning the infusion of esmolol. Mechanical arrest was achieved before electrical arrest. In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts. The concentrations of esmolol varied from 0.084 to 6.7 mmol/L and from 0.12 to 1.45 mmol/L in the rat and rabbit heart experiments, respectively. In the third protocol, the effects of 20 minutes of normothermic (37°C) ischemia on the function of isolated rat hearts perfused with esmolol-containing Krebs solution were compared with those using high-potassium (25 mmol/L) Krebs solution. Group A subjects (n = 9) received the ischemic injury after being perfused (and arrested) for 20 minutes with either esmolol or potassium (KCl, 25 mmol/L). Group B subjects (n = 10) received the same ischemic insult before being perfused with either esmolol or potassium. Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of ±dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009). Finally, the fourth protocol was done to evaluate the effects of esmolol in a clinically relevant experimental model. Pigs were divided into esmolol (n = 6) and potassium (n = 5) groups and subjected to normothermic cardiopulmonary bypass and a 1-hour period of cardiac arrest. Twenty minutes after stopping infusion of the cardioplegic agents, all animals were weaned off bypass. There were no statistically significant differences between the groups. Conclusions. Esmolol hydrochloride can be used as effectively as potassium for inducing and maintaining predictable and reversible cardiac arrest during normothermic cardiac operations.

Original languageEnglish
Pages (from-to)721-727
Number of pages7
JournalAnnals of Thoracic Surgery
Volume63
Issue number3
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Induced Heart Arrest
Hyperkalemia
Potassium
Ventricular Pressure
Heart Arrest
esmolol
Rabbits
Blood Pressure
Cardiopulmonary Bypass
Theoretical Models
Swine
Ischemia
Perfusion
Heart Rate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Ede, M., Ye, J., Gregorash, L., Summers, R., Pargaonkar, S., LeHouerou, D., ... Deslauriers, R. (1997). Beyond hyperkalemia: β-blocker-induced cardiac arrest for normothermic cardiac operations. Annals of Thoracic Surgery, 63(3), 721-727. https://doi.org/10.1016/S0003-4975(96)01114-9

Beyond hyperkalemia : β-blocker-induced cardiac arrest for normothermic cardiac operations. / Ede, Mauricio; Ye, Jian; Gregorash, Lori; Summers, Randy; Pargaonkar, Shirish; LeHouerou, Daniel; Lessana, Arrigo; Salerno, Tomas; Deslauriers, Roxanne.

In: Annals of Thoracic Surgery, Vol. 63, No. 3, 01.01.1997, p. 721-727.

Research output: Contribution to journalArticle

Ede, M, Ye, J, Gregorash, L, Summers, R, Pargaonkar, S, LeHouerou, D, Lessana, A, Salerno, T & Deslauriers, R 1997, 'Beyond hyperkalemia: β-blocker-induced cardiac arrest for normothermic cardiac operations', Annals of Thoracic Surgery, vol. 63, no. 3, pp. 721-727. https://doi.org/10.1016/S0003-4975(96)01114-9
Ede, Mauricio ; Ye, Jian ; Gregorash, Lori ; Summers, Randy ; Pargaonkar, Shirish ; LeHouerou, Daniel ; Lessana, Arrigo ; Salerno, Tomas ; Deslauriers, Roxanne. / Beyond hyperkalemia : β-blocker-induced cardiac arrest for normothermic cardiac operations. In: Annals of Thoracic Surgery. 1997 ; Vol. 63, No. 3. pp. 721-727.
@article{1140dbe9110d43aa808ef1a6fcc994da,
title = "Beyond hyperkalemia: β-blocker-induced cardiac arrest for normothermic cardiac operations",
abstract = "Background. Four experimental protocols were carried out to assess the ability of esmolol to induce and maintain reversible cardiac arrest under continuous normothermic (37°C) perfusion. Methods and results. In the first protocol, 8 perfused rat hearts were subjected to 20, 60, 90, and 120 minutes of esmolol arrest, after which positive and negative first derivative of pressure, heart rate, left ventricular developed pressure, and left ventricular end-diastolic pressure were evaluated. Arrest was achieved 45 to 60 seconds after beginning the infusion of esmolol. Mechanical arrest was achieved before electrical arrest. In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts. The concentrations of esmolol varied from 0.084 to 6.7 mmol/L and from 0.12 to 1.45 mmol/L in the rat and rabbit heart experiments, respectively. In the third protocol, the effects of 20 minutes of normothermic (37°C) ischemia on the function of isolated rat hearts perfused with esmolol-containing Krebs solution were compared with those using high-potassium (25 mmol/L) Krebs solution. Group A subjects (n = 9) received the ischemic injury after being perfused (and arrested) for 20 minutes with either esmolol or potassium (KCl, 25 mmol/L). Group B subjects (n = 10) received the same ischemic insult before being perfused with either esmolol or potassium. Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of ±dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009). Finally, the fourth protocol was done to evaluate the effects of esmolol in a clinically relevant experimental model. Pigs were divided into esmolol (n = 6) and potassium (n = 5) groups and subjected to normothermic cardiopulmonary bypass and a 1-hour period of cardiac arrest. Twenty minutes after stopping infusion of the cardioplegic agents, all animals were weaned off bypass. There were no statistically significant differences between the groups. Conclusions. Esmolol hydrochloride can be used as effectively as potassium for inducing and maintaining predictable and reversible cardiac arrest during normothermic cardiac operations.",
author = "Mauricio Ede and Jian Ye and Lori Gregorash and Randy Summers and Shirish Pargaonkar and Daniel LeHouerou and Arrigo Lessana and Tomas Salerno and Roxanne Deslauriers",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0003-4975(96)01114-9",
language = "English",
volume = "63",
pages = "721--727",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Beyond hyperkalemia

T2 - β-blocker-induced cardiac arrest for normothermic cardiac operations

AU - Ede, Mauricio

AU - Ye, Jian

AU - Gregorash, Lori

AU - Summers, Randy

AU - Pargaonkar, Shirish

AU - LeHouerou, Daniel

AU - Lessana, Arrigo

AU - Salerno, Tomas

AU - Deslauriers, Roxanne

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Background. Four experimental protocols were carried out to assess the ability of esmolol to induce and maintain reversible cardiac arrest under continuous normothermic (37°C) perfusion. Methods and results. In the first protocol, 8 perfused rat hearts were subjected to 20, 60, 90, and 120 minutes of esmolol arrest, after which positive and negative first derivative of pressure, heart rate, left ventricular developed pressure, and left ventricular end-diastolic pressure were evaluated. Arrest was achieved 45 to 60 seconds after beginning the infusion of esmolol. Mechanical arrest was achieved before electrical arrest. In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts. The concentrations of esmolol varied from 0.084 to 6.7 mmol/L and from 0.12 to 1.45 mmol/L in the rat and rabbit heart experiments, respectively. In the third protocol, the effects of 20 minutes of normothermic (37°C) ischemia on the function of isolated rat hearts perfused with esmolol-containing Krebs solution were compared with those using high-potassium (25 mmol/L) Krebs solution. Group A subjects (n = 9) received the ischemic injury after being perfused (and arrested) for 20 minutes with either esmolol or potassium (KCl, 25 mmol/L). Group B subjects (n = 10) received the same ischemic insult before being perfused with either esmolol or potassium. Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of ±dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009). Finally, the fourth protocol was done to evaluate the effects of esmolol in a clinically relevant experimental model. Pigs were divided into esmolol (n = 6) and potassium (n = 5) groups and subjected to normothermic cardiopulmonary bypass and a 1-hour period of cardiac arrest. Twenty minutes after stopping infusion of the cardioplegic agents, all animals were weaned off bypass. There were no statistically significant differences between the groups. Conclusions. Esmolol hydrochloride can be used as effectively as potassium for inducing and maintaining predictable and reversible cardiac arrest during normothermic cardiac operations.

AB - Background. Four experimental protocols were carried out to assess the ability of esmolol to induce and maintain reversible cardiac arrest under continuous normothermic (37°C) perfusion. Methods and results. In the first protocol, 8 perfused rat hearts were subjected to 20, 60, 90, and 120 minutes of esmolol arrest, after which positive and negative first derivative of pressure, heart rate, left ventricular developed pressure, and left ventricular end-diastolic pressure were evaluated. Arrest was achieved 45 to 60 seconds after beginning the infusion of esmolol. Mechanical arrest was achieved before electrical arrest. In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts. The concentrations of esmolol varied from 0.084 to 6.7 mmol/L and from 0.12 to 1.45 mmol/L in the rat and rabbit heart experiments, respectively. In the third protocol, the effects of 20 minutes of normothermic (37°C) ischemia on the function of isolated rat hearts perfused with esmolol-containing Krebs solution were compared with those using high-potassium (25 mmol/L) Krebs solution. Group A subjects (n = 9) received the ischemic injury after being perfused (and arrested) for 20 minutes with either esmolol or potassium (KCl, 25 mmol/L). Group B subjects (n = 10) received the same ischemic insult before being perfused with either esmolol or potassium. Esmolol-treated hearts showed better recovery than those receiving potassium, in terms of ±dP/dt (p < 0.01), left ventricular systolic pressure (p < 0.01), and left ventricular developed pressure (p < 0.009). Finally, the fourth protocol was done to evaluate the effects of esmolol in a clinically relevant experimental model. Pigs were divided into esmolol (n = 6) and potassium (n = 5) groups and subjected to normothermic cardiopulmonary bypass and a 1-hour period of cardiac arrest. Twenty minutes after stopping infusion of the cardioplegic agents, all animals were weaned off bypass. There were no statistically significant differences between the groups. Conclusions. Esmolol hydrochloride can be used as effectively as potassium for inducing and maintaining predictable and reversible cardiac arrest during normothermic cardiac operations.

UR - http://www.scopus.com/inward/record.url?scp=0030938252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030938252&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(96)01114-9

DO - 10.1016/S0003-4975(96)01114-9

M3 - Article

VL - 63

SP - 721

EP - 727

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -